PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
August 23, 2024Deleted Journal4 citationsOpen Access

Serious Adverse Events Following COVID 19 Vaccination in India: A Retrospective Study

View Full Paper
SPSruthikrishna PunathukandiJTJayakrishnan ThayyilGovernment Medical CollegeMNMeera Surendran NairPennsylvania State University

Key Points

Key points are not available for this paper at this time.

Abstract

Abstract Introduction: The aim of this study was to identify the type and detail the serious adverse events following COVID-19 vaccination in India. Materials and Methods: The descriptive study was conducted by extracting the data from the website by the Ministry of Health and Family Welfare, Government of India https://shorturl.at/imwJY. The variables analysed were types of vaccines, types of SAEFI, thromboembolic (TE) events, neurological manifestations and consistent causal association as per the World Health Organization. Data were entered into MS Excel and analysed using the SPSS software version 25. Results: Out of the total 1.9 billion doses of COVID-19 vaccines, 1527 cases of SAEFI were reported. Among these, 51.7% were coincidental and 30.8% were associated with vaccination. All the allergic reactions (58), anaphylaxis (50), TE events (342) and Guillain–Barre syndrome (41) had consistent causal association. Out of the 598 deaths, 2% of deaths had consistent causal association. In comparison of exposure to Covaxin, Covishield had high odds of death (odds ratio OR =1.5; 95% confidence interval CI =1.11–2.07), acute febrile illness (OR = 2.07; 95% CI = 1–4.3), TE events (OR = 1.58; 95% CI = 1.08–2.31) and cardiovascular events (OR = 2.03; 95% CI = 1.32–3.13). Conclusions: Compared to other countries, similar types of SAEFIs were reported from India but at a lower rate.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Punathukandi et al. (2024) studied this question.

synapsesocial.com/papers/68e5b277b6db64358754b36bhttps://doi.org/10.4103/pmrr.pmrr_79_24
Ask AI
Helpful
Bookmark
Share
View Full Paper